{
    "root": "fd3a5cc6-5bbe-4690-8d20-f3508a309131",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Trintellix",
    "value": "20250304",
    "ingredients": [
        {
            "name": "VORTIOXETINE HYDROBROMIDE",
            "code": "TKS641KOAY"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults.",
    "contraindications": "• The recommended starting dose is 10 mg administered orally once daily without regard to meals ( 2.1 ). • The dose should then be increased to 20 mg/day, as tolerated ( 2.1 ). • Consider 5 mg/day for patients who do not tolerate higher doses ( 2.1 ). • TRINTELLIX can be discontinued abruptly. However, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for one week prior to full discontinuation if possible ( 2.3 ). • The maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers ( 2.5 ).",
    "warningsAndPrecautions": "TRINTELLIX tablets are available as follows:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Features\n                              \n                           \n                           \n                              \n                                 Strengths\n                              \n                           \n                        \n                        \n                           \n                              \n                                 10 mg\n                              \n                           \n                           \n                              \n                                 20 mg\n                              \n                           \n                        \n                        \n                           \n                              Color\n                           \n                           \n                              yellow\n                           \n                           \n                              red\n                           \n                        \n                        \n                           \n                              Debossment\n                           \n                           \n                              \"10\" on one side of tablet \"TL\" on other side of tablet\n                           \n                           \n                              \"20\" on one side of tablet \"TL\" on other side of tablet\n                           \n                        \n                        \n                           \n                              \n                                 Presentations and NDC Codes\n                              \n                           \n                           \n                              Bottles of approximately 2520 tablets, NDC 55154-0256-8\n                           \n                           \n                              Bottles of approximately 2430 tablets, NDC 55154-0257-8",
    "adverseReactions": "•Hypersensitivity to vortioxetine or any component of the formulation. Hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in patients treated with TRINTELLIX [see Adverse Reactions (6.2)].\n                     \n                        •The use of MAOIs intended to treat psychiatric disorders with TRINTELLIX or within 21 days of stopping treatment with TRINTELLIX is contraindicated because of an increased risk of serotonin syndrome. The use of TRINTELLIX within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.4), Warnings and Precautions (5.2)]. Starting TRINTELLIX in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2)]."
}